# Olmesartan medoxomil

## Olmetec 40mg

| TAH Drug Code      | [**OOLM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OOLM)                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Hypertension: Treatment of hypertension with or without concurrent use of other antihypertensive agents                                                                                                                                                                                                                       |
| Dosing             | HTN: initial 20mg QD, after 2weeks may titrate up to 40mg QD.                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Concomitant use with aliskiren in patients with diabetes mellitus Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2) |
| Adverse Effects    | 1% to 10%: Central nervous system: Dizziness, headache Endocrine & metabolic: Hyperglycemia, hypertriglyceridemia Gastrointestinal: Diarrhea Neuromuscular & skeletal: Back pain, CPK increased Renal: Hematuria Respiratory: Bronchitis, pharyngitis, rhinitis, sinusitis Miscellaneous: Flu-like syndrome                   |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3rd Trimesters                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                 |

